Procurement
Expert Panel
Create New Account
Login
logo
Report store
Insights
Survey
Consulting
Book discovery call
logo

India Insulin Market Review to 2018

Intensifying Strategic Alliances Between Companies

Region:Asia

Product Code:KR247

Download Sample Report
Published On

September 2014

Total pages

78

About the Report

The industry research publication titled ‘India Insulin Market Review to 2018 - Intensifying Strategic Alliances Between Companies’ presents a comprehensive analysis of market size by value of major types (human insulin, analog insulin, premix, rapid-acting, long-acting) of insulin consumed in India. The report entails the segment-wise market share analysis and company profiles of major players in the insulin market in India. Future prospects and opportunities in the market have also been discussed in the report. 
The economic advancement of any country is paradoxical in nature. While on one hand, it increases the affluence of the masses, the other side is characterized by diseases that are accompanied by passive lifestyles. From the several diseases caused by a sedentary form of life such as cardiovascular ailments, hypertension, and high blood pressure, diabetes is also increasing at an alarming rate, especially in the developing countries. India was resident to nearly 61.5 million people suffering from diabetes in 2013, which is the second-largest in the world after China. The prevalence of diabetes has made it the fifth-largest disease in India.
Diabetes in India is reaching epidemic proportions. Rapid cultural changes such as increasing urbanization, modified diet patterns and sedentary lifestyles among the young generation, have heightened the prevalence of diabetes in India. In 2013, while 61.5 million people suffered from diabetes in the country, another 30 million were in the pre-diabetes group. Medication for the diabetic population is the need of the hour since the disease is adding significantly to the mortality rate of India.
In FY’2008, the revenue generated by the sales of insulin in India was estimated to be USD ~ million and reached USD ~ million in FY’2013, following at a CAGR of 13.9% during the period. The Indian insulin market is witnessing the development and has yet to mature. With a huge base of diabetic patients, it is anticipated that only 25% of this population is receiving treatment. Unawareness backed by low affordability has left the major proportion of the diabetic populace to remain untreated. However, since higher disposable income is increasing the accessibility to healthcare services, enhanced diagnostics will further broaden the patient base, creating opportunities for insulin companies operating in India.
The diabetic population in India is largely treated with human insulin solely due to the fact that it is cheaper as compared to analog insulin. In FY’2013, human insulin held ~% of the total insulin market in India, generating revenue of USD ~ million. The revenue from human insulin registered a CAGR of 10.5% during FY’2008-FY’2013. Although the share of human insulin has been more since FY’2008, the market captured by analog insulin has been growing rapidly with a CAGR of 20.4% during FY’2008-FY’2013, increasing its share from ~% in FY’2008 to ~% in FY’2013.
India has become a very lucrative market for insulin multinationals. Companies including Novo Nordisk, Eli Lilly, and Sanofi dominate the landscape and had a share of more than 85% in the Indian insulin market in FY’2013. With superior product portfolios and marketing strategies, the 3 companies have gained a monopoly over the market. Domestic enterprises including Biocon and Wockhardt, therefore, face stiff competition from foreign counterparts. 
Key Topics Covered in the Report:
  • The market size of India insulin market in terms of revenue
  • Market segmentation by insulin replacement therapy and types of insulin
  • Government regulation and support schemes for the Indian insulin market
  • Pricing scenario of different insulin brands in India
  • Trends and developments in India insulin market
  • Growth drivers and challenges in India insulin market
  • Market share of major players in the insulin market in India
  • Market share and Revenue of major brands by types of insulin
  • Company profiles of major players in the Indian insulin market
  • Future outlook and projections of the insulin market in India
  • Macroeconomic factors affecting the insulin market in India 

Products

Insulin, Human Insulin, Analog Insulin, Premix, Rapid Acting, Long Acting, diabetes, Market Size, Market Share, Price of Insulin, diabetic population

Companies

Novo Nordisk India Private Limited, Eli Lilly and Company India Private Limited, Sanofi India Limited, Biocon Limited, Wockhardt Limited

Table of Contents

1. Asia Pacific Insulin Market Introduction

1.1. Asia Pacific Insulin Market Value Chain

1.2. Asia Pacific Insulin Market Size by Value, 2008-2013

1.3. Asia Pacific Insulin Market Segmentation, 2008-2013

1.3.1. By Geography, 2008-2013

1.3.2. By Insulin Replacement Therapy (Human Insulin and Analog Insulin), 2013

1.3.3. By Types of Insulin (Premix, Rapid Acting, Long Acting), 2013

1.4. New Product Development By Major Insulin Companies

1.5. Trends and Developments in Asia Pacific Insulin Market

Monopoly of Foreign Brands

Phasing Out of Human Insulin

1.6. Growth Drivers and Challenges in Asia Pacific Insulin Market

Shift from Human Insulin to Analog Insulin

Rising Prevalence of Diabetes

Increasing Diabetes Care Expenditure

Low Affordability

Lack of Awareness

1.7. SWOT Analysis of Asia Insulin Market

1.8. Asia Pacific Insulin Market Future Outlook and Projections, 2014-2018

1.8.1. By Geography, 2014-2018

2. India Insulin Market Introduction

3. India Insulin Market Size, FY"2008-FY"2013

4. India Insulin Market Segmentation, FY"2008-FY"2013

4.1. By Insulin Replacement Therapy (Human Insulin and Analog Insulin), FY"2008-FY"2013

4.2. By Types of Insulin (Premix, Rapid Acting, long Acting), FY"2008-FY"2013

4.3. Usage by Type of Diabetes, FY"2008-FY"2013

5. Government Regulations and Support Schemes in India Insulin Market

5.1. National Pharmaceutical Pricing Authority (NPPA)

Implications of Pricing Limits by NPPA

5.2. National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS)

6. Pricing Scenario in India Insulin Market

7. Trends and Developments in India Insulin Market

Price Gap Between Foreign and Domestic Insulin Brands

Shift of Diabetes to Young Age Group

Strategic Alliances in India Insulin Market

8. Growth Drivers and Challenges in India Insulin Market

Increasing Diabetic Population

Increasing Expenditure on Diabetes Care

Exchange Rate Fluctuation

9. Market Share of Major Companies in India Insulin Market, FY"2013

9.1. By Type of Insulin, FY"2013

9.1.1. By Premix Insulin, FY"2013

9.1.2. By Long Acting Insulin, FY"2013

9.1.3. By Rapid Acting Insulin, FY"2013

10. Company Profiles of Major Players in India Insulin Market

10.1. Novo Nordisk India Pvt. Ltd

10.1.1. Company Overview

10.1.2. Business Strategies

Market Expansion Through Spreading Awareness

Strengthening Research and Development (R&D) Activities

10.1.3. Competitive Standing

10.2. Eli Lilly and Company India Pvt. Ltd.

10.2.1. Company Overview

10.2.2. Business Strategies

Focus on Increasing R&D Investment in India

Concentration Towards the Diabetes Care Segment

10.2.3. Competitive Standing

10.3. Sanofi India Ltd.

10.3.1. Company Overview

10.3.2. Business Strategies

Commence Insulin Production in India

Product Innovation

Patient Awareness Programs

10.3.3. Competitive Standing

10.4. Biocon Ltd.

10.4.1. Company Overview

10.4.2. Competitive Standing

10.5. Wockhardt Ltd.

10.5.1. Company Overview

10.5.2. Competitive Standing

11. India Insulin Market Future Outlook and Projections, 2014-2018

11.1. By Insulin Replacement Therapy (Human Insulin and Analog Insulin, FY"2014-FY"2018

11.2. Cause and Effect Relationship Between Dependable and Independent Variable Factors prevailing in India Insulin Market

12. Macroeconomic Factors in India Insulin Market, 2008-2018

12.1. Diabetic Population in India, 2008-2018

12.2. India Government Spending on Healthcare, FY"2008-FY"2018

12.3. India Consumer Spending on Healthcare, FY"2008-FY"2018

12.4. India Personal Disposable Income, FY"2008-FY"2018

13. Appendix

13.1. Market Definitions

13.2. Abbreviations

13.3. Research Methodology

Data Collection Methods

Approach

Variables (Dependent and Independent)

Final Conclusion

13.4. Disclaimer

Why Buy From Us?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022